Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors.
Saved in:
| Title: | Discovery and pharmacological characterization of AZD3229, a potent KIT/PDGFRα inhibitor for treatment of gastrointestinal stromal tumors. |
|---|---|
| Authors: | Banks E; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Grondine M; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Bhavsar D; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Barry E; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Kettle JG; Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK., Reddy VP; DMPK, Oncology R&D, AstraZeneca, Cambridge, CB10 1XL, UK., Brown C; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Wang H; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Mettetal JT; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Collins T; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK., Adeyemi O; Functional and Mechanistic Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK., Overman R; Discovery Sciences, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK., Lawson D; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Harmer AR; Functional and Mechanistic Safety, Clinical Pharmacology and Safety Sciences, R&D, AstraZeneca, Cambridge CB4 0WG, UK., Reimer C; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Drew L; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Packer MJ; Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK., Cosulich S; Projects, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK ., Jones RD; DMPK, Oncology R&D, AstraZeneca, Cambridge, CB10 1XL, UK., Shao W; Projects, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Wilson D; Chemistry, Oncology R&D, AstraZeneca, Cambridge CB4 0WG, UK., Guichard S; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Fawell S; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA., Anjum R; Bioscience, Oncology R&D, AstraZeneca, 35 Gatehouse Park, Boston, MA 02451, USA. rana.anjum@astrazeneca.com. |
| Source: | Science translational medicine [Sci Transl Med] 2020 Apr 29; Vol. 12 (541). |
| Publication Type: | Journal Article; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: American Association for the Advancement of Science Country of Publication: United States NLM ID: 101505086 Publication Model: Print Cited Medium: Internet ISSN: 1946-6242 (Electronic) Linking ISSN: 19466234 NLM ISO Abbreviation: Sci Transl Med Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
